{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T02:59:12Z","timestamp":1762052352638,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>A 49-year-old female was admitted to our hospital with malaise and gross hematuria. As ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13) activity was absent and the ADAMTS13 inhibitor was detected, she was diagnosed with acquired thrombotic thrombocytopenic purpura (TTP). In addition to plasma exchange and corticosteroid therapy, she received rituximab therapy for inhibitor boosting but died suddenly of a cardiac arrest on day 9. The postmortem revealed microvascular platelet thrombi in multiple organs. In this case, the deterioration of the patient\u2019s clinical status was considered to have been caused by inhibitor boosting-induced systemic microvascular occlusion. In particular, her sudden death may have been due to cardiovascular microthrombosis. Since inhibitor boosting can cause TTP patients to deteriorate rapidly, it is crucial to manage TTP patients who undergo inhibitor boosting appropriately. The monitoring of cardiac complications in TTP patients may also be essential, especially in the acute phase.<\/jats:p>","DOI":"10.3390\/hematolrep14020027","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T04:46:23Z","timestamp":1654145183000},"page":"203-209","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sudden Cardiac Death in a Patient with Thrombotic Thrombocytopenic Purpura: A Case Report"],"prefix":"10.3390","volume":"14","author":[{"given":"Kikuaki","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8060-6683","authenticated-orcid":false,"given":"Shogo","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7700-5262","authenticated-orcid":false,"given":"Toshiki","family":"Mushino","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hosoi","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-0970","authenticated-orcid":false,"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-1836","authenticated-orcid":false,"given":"Kinta","family":"Hatakeyama","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cerebral and Cardiovascular Center, Osaka 5648565, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion Medicine, Nara Medical University, Nara 6348521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sonoki","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 6418509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan","volume":"106","author":"Matsumoto","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-016-2019-x","article-title":"Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy","volume":"104","author":"Miyakawa","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: An international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/trf.13182","article-title":"Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: Visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma","volume":"55","author":"Isonishi","year":"2015","journal-title":"Transfusion"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0609.2009.01292.x","article-title":"Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: A report of four cases and a systematic review of the literature","volume":"83","author":"Elliott","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2169\/internalmedicine.3722-19","article-title":"Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sj\u00f6gren\u2019s Syndrome and Primary Hypothyroidism","volume":"59","author":"Okumura","year":"2020","journal-title":"Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4330\/wjc.v10.i12.254","article-title":"Cardiac implications of thrombotic thrombocytopenic purpura","volume":"10","author":"Wiernek","year":"2018","journal-title":"World J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13000-015-0285-1","article-title":"An autopsy case of myocardial infarction due to idiopathic thrombotic thrombocytopenic purpura","volume":"10","author":"Tasaki","year":"2015","journal-title":"Diagn. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40744-020-00265-w","article-title":"Sjogren\u2019s Syndrome Associated with Thrombotic Thrombocytopenic Purpura: A Case-Based Review","volume":"8","author":"Carvalho","year":"2021","journal-title":"Rheumatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6869342","DOI":"10.1155\/2021\/6869342","article-title":"Sequential Immune Thrombocytopenia (ITP) and Thrombotic Thrombocytopenic Purpura (TTP) in an Elderly Male Patient with Primary Sjogren\u2019s Syndrome: When in Doubt, Use the PLASMIC Score","volume":"2021","author":"Miller","year":"2021","journal-title":"Case Rep. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1598","DOI":"10.1097\/MD.0000000000001598","article-title":"Risk Factors for Autoimmune Diseases Development after Thrombotic Thrombocytopenic Purpura","volume":"94","author":"Roriz","year":"2015","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1002\/ajh.23126","article-title":"Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura","volume":"87","author":"George","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/14\/2\/27\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:23:38Z","timestamp":1760138618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/14\/2\/27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["hematolrep14020027"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep14020027","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}